BACKGROUND: Chitinase 3-like 1 (CHI3L1) is upregulated in a wide variety of inflammatory conditions. Recent studies have pointed to a role of CHI3L1 in multiple sclerosis (MS) pathogenesis. OBJECTIVE: The objective of this study was to investigate the role of plasma CHI3L1 in MS clinical course and disease activity and to evaluate the effect of interferon-beta (IFNβ) treatment on protein levels. METHODS: Plasma CHI3L1 levels were determined by ELISA in 57 healthy controls (HC), 220 untreated MS patients [66 primary progressive MS patients (PPMS), 30 secondary progressive MS patients (SPMS), and 124 relapsing-remitting MS patients (RRMS), 94 during clinical remission and 30 during relapse], and 32 MS patients receiving IFNβ treatment. A polymorphism of the CHI3L1 gene, rs4950928, was genotyped in 3274 MS patients and 3483 HC. RESULTS: Plasma CHI3L1 levels were significantly increased in patients with progressive forms of MS compared with RRMS patients and HC. CHI3L1 levels were similar between RRMS patients in relapse and remission. A trend towards decreased CHI3L1 levels was observed in IFNβ-treated patients. Allele C of rs4950928 was significantly associated with PPMS patients and with higher plasma CHI3L1 levels. CONCLUSIONS: These findings point to a role of CHI3L1 in patients with progressive forms of MS, particularly in those with PPMS.
BACKGROUND:Chitinase 3-like 1 (CHI3L1) is upregulated in a wide variety of inflammatory conditions. Recent studies have pointed to a role of CHI3L1 in multiple sclerosis (MS) pathogenesis. OBJECTIVE: The objective of this study was to investigate the role of plasma CHI3L1 in MS clinical course and disease activity and to evaluate the effect of interferon-beta (IFNβ) treatment on protein levels. METHODS: Plasma CHI3L1 levels were determined by ELISA in 57 healthy controls (HC), 220 untreated MSpatients [66 primary progressive MSpatients (PPMS), 30 secondary progressive MSpatients (SPMS), and 124 relapsing-remitting MSpatients (RRMS), 94 during clinical remission and 30 during relapse], and 32 MSpatients receiving IFNβ treatment. A polymorphism of the CHI3L1 gene, rs4950928, was genotyped in 3274 MSpatients and 3483 HC. RESULTS: Plasma CHI3L1 levels were significantly increased in patients with progressive forms of MS compared with RRMS patients and HC. CHI3L1 levels were similar between RRMS patients in relapse and remission. A trend towards decreased CHI3L1 levels was observed in IFNβ-treated patients. Allele C of rs4950928 was significantly associated with PPMS patients and with higher plasma CHI3L1 levels. CONCLUSIONS: These findings point to a role of CHI3L1 in patients with progressive forms of MS, particularly in those with PPMS.
Authors: Eva Borràs; Ester Cantó; Meena Choi; Luisa Maria Villar; José Carlos Álvarez-Cermeño; Cristina Chiva; Xavier Montalban; Olga Vitek; Manuel Comabella; Eduard Sabidó Journal: Mol Cell Proteomics Date: 2015-11-09 Impact factor: 5.911
Authors: Sara Gil-Perotin; Jessica Castillo-Villalba; Laura Cubas-Nuñez; Raquel Gasque; David Hervas; Josep Gomez-Mateu; Carmen Alcala; Francisco Perez-Miralles; Francisco Gascon; Jose Andres Dominguez; Bonaventura Casanova Journal: Front Neurol Date: 2019-09-23 Impact factor: 4.003
Authors: Marta Del Campo; Daniela Galimberti; Naura Elias; Lynn Boonkamp; Yolande A Pijnenburg; John C van Swieten; Kelly Watts; Silvia Paciotti; Tommaso Beccari; William Hu; Charlotte E Teunissen Journal: Ann Clin Transl Neurol Date: 2018-09-07 Impact factor: 4.511